Mobocertinib, (LuciMob) works for treating lung cancer.  Mobocertinib is an unmet breakthrough for NSCLC with EGFR ex20ins+. Mobocertinib is the first and only approved effective drug for EGFR ex20ins+. In china, lung cancer is the most Frequently diagnosed cancer, and NSCLC accounts for 80% of all lung cancer cases. Of those patients diagnosed with EGFR-mutated NSCLC, up to 10% have harbor exon20 insertions. Mobocertinib is a doctor prescription (Mobocertinib) medicine.

Lucius Pharma Ltd. of Laos mfg LuciMob. Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. LuciMob Capsule may be taken with or without food, but it is better to take it at a fixed time.

Suggestion:

Genuine medicine is important for treatment. So, always try to source genuine medicines from authentic sources and check the quality of medicines.

Side effects:

The most common side effects of MOBOCERTINIB are:

Diarrhea, nausea, vomiting, loss of appetite, stomach/abdominal pain, heartburn, mouth sores. Tell your doctor or pharmacist right away if any of these side effects persist or worsen.

Remember that your doctor has prescribed this medication because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.

Tell your doctor right away if you have any serious side effects, including: pain/swelling/redness around the nails, signs of eye problems (such as vision changes, eye redness/pain, eye discharge), signs of kidney problems (such as change in the amount of urine), signs of heart failure (such as shortness of breath, swelling ankles/feet, unusual tiredness, unusual/sudden weight gain).

Take this medication regularly to get the most benefit from it. To help you remember, take it at the same times on the days your doctor directs.

This is not a complete list of possible side effects. Contact your doctor or pharmacist if you have any other side effects not listed above.